• Sign in

  • Join for free
  • Donate Today!
  • We are Social
    • Facebook
    • Twitter
    • Instagram
    • YouTube
    • LinkedIn
  • Who
    we are
    • Who we are
    • Our Story
    • Rosie
    • Rosie’s Blog
    • Our Trustees
    • Our Patrons
  • What
    we do
  • Secondary
    Breast Cancer
    • What is secondary breast cancer?
    • Symptoms
    • What is the current treatment
    • Maximising quality of life
    • Your Stories
    • Where to go for information
  • Get
    involved
    • Our Fundraisers
    • How to fundraise
    • Events
      • Fonthill Open Garden Party
      • Past Events
  • News
    • News
    • In the media
    • Video
    • Rosie’s Blog
  • Contact
Secondary1st
  • Donate Today!

Search

Login

Register
  • 020 8905 3955info@secondary1st.org.uk
0
Secondary1st
  • Menu
  • Who
    we are
    • Who we are
    • Our Story
    • Rosie
    • Rosie’s Blog
    • Our Trustees
    • Our Patrons
  • What
    we do
  • Secondary
    Breast Cancer
    • What is secondary breast cancer?
    • Symptoms
    • What is the current treatment
    • Maximising quality of life
    • Your Stories
    • Where to go for information
  • Get
    involved
    • Our Fundraisers
    • How to fundraise
    • Volunteer
    • Events
      • Fonthill Open Garden Party
      • Past Events
  • News & Media
    • News
    • In the media
    • Video
    • Rosie’s Blog
  • Contact
  • Donate Today!
27July

NICE Approval for Two Breast Cancer Drugs

Next
Previous
July 27, 2022
By cuco_admin_sec
0 Comment

Final draft guidance from NICE now recommends that two drugs to treat two different types of secondary or metastatic breast cancer be made available through the Cancer Drugs Fund.   Piqray or alpelisib is a kinase inhibitor made by Novartis Pharmaceuticals UK.  It is to be used with fulvestrant, the hormonal therapy, to treat hormone receptor positive HER2-negative in those with a mutation in the PIK3CA gene who have locally advanced or metastatic breast cancer which has grown after treatment with combined hormonal therapy and a cancer growth inhibitor.  Piqray is taken as one tablet a day.

Trodelvy or sacituzumab govitecan is made by Gilead Sciences and is to be used for locally advanced or metastatic triple negative breast cancer which cannot be removed by surgery and after two or more lines of systemic therapies .  It has two elements, a monoclonal antibody to recognize and attach to a protein on the surface of cancer cells and a topoisomerase inhibitor to prevent the cancer cells multiplying and eventually cause them to die.  Trodelvy is administered via infusion.

Categories: News

be first to comment Cancel reply

Your Name*

Your Email*

Message*

  • Search

  • Sign up for Newsletter

    * = required field
  • Categories

    • Event
    • Fundraising
    • In the media
    • News
    • Past Events
    • Rosie's blog
    • Uncategorised
    • Your Stories
  • Latest News

    • Walking the Wall

      July 27, 2022

    • NICE Approval for Two Breast Cancer Drugs

      July 27, 2022

    • Walking the Wall

      June 09, 2022

    • A New Breast Cancer Drug

      June 09, 2022

  • Who We Are

    • Who we are
    • Our Story
    • Rosie
    • Rosie’s blog
    • Our Trustees
    • Our Patrons
  • What We Do

    • What we do
  • Secondary Breast Cancer

    • What is secondary breast cancer?
    • Symptoms
    • What is the current treatment
    • Maximising quality of life
    • Where to go for information
  • Get Involved

    • How to fundraise
    • Our Fundraisers

© 2016 - 2022 Secondary First is a Company Limited by Guarantee. Registered in England and Wales No. 9920657. Registered Office: 1st Floor Healthaid House, Marlborough Hill, Harrow, HA1 1UD. It is a Registered Charity Number 1165614.
Site maintained by CuCo Creative.

  • Cookie Policy
  • Privacy Policy